Abstract:Key PointsBiofilm bacteria have been demonstrated to be significant contributors to human disease, yet our understanding of the nature of biofilm infections and their effective treatment remains underdeveloped. Recent research has begun to unlock many of the mysteries associated with biofilm infections; however, substantial research will be necessary before adequate control of biofilm infections will be generally attainable.Biofilms have been shown to be generally more resistant to antimicrobial chemotherapies than free-living bacteria. No current consensus exists regarding the mechanisms of biofilm resistance to antibacterial agents. Numerous competing theories are presently under investigation, yet the phenomenon of biofilm resistance remains a subject generating many questions but few answers.Multiple factors appear to contribute to the overall resistance of biofilm bacteria. These include reduced metabolic and growth rates, protection by extracellular polymeric substances and specific resistance mechanisms conferred by the altered physiology of biofilm bacteria compared with planktonic bacteria.The failure of antibacterial agents to rapidly penetrate into all areas of a biofilm has been considered as a contributing factor to biofilm resistance. Reports indicate that species-composition of biofilms and the choice of antibiotic have a marked impact on antibiotic penetration.Biofilm cells have been shown by a number of investigators to have reduced growth rates, and this is believed to impact the effectiveness of antibiotics that target rapidly multiplying cells. Therefore, antibiotics such as the fluoroquinolones or macrolides may be better therapeutic choices than β-lactams when treating biofilm infections.Altered physiological states of biofilm cells compared with planktonic cells have been demonstrated for a number of bacteria. The activation of specific resistance genes in biofilms has been demonstrated in a few instances. Specific resistance mechanisms should, therefore, be considered when treating biofilm infections.A number of alternative approaches to antibacterial treatment have been proposed for biofilms. Many of these are non-lethal treatments that are expected to enhance the activity of currently used antibiotics. For example, manipulation of electrical fields has shown some promise in enhancing the activity of certain antibiotics against biofilms. The finding that in certain bacteria autoinducers mediate the production of virulence factors, and possibly also biofilm formation, has led to developmental work on autoinducer-blocking agents. These blocking agents are expected, in certain cases, to limit disease progression at the same time as antibiotics are being administered, and, in other cases, to act to enhance the activity of an antibiotic. Biofilm-dispersion agents are currently under development and are anticipated to result in improved access of antibiotics to bacteria, and possibly to alter the physiological status of the bacteria making them more susceptible to antibiotic exposure.The current state of the field indicates that enhanced antimicrobial resistance is a general trait of biofilms and is the result of numerous specific factors which depend on the species involved, the environment of the biofilm and the antimicrobial agent used. It is expected, therefore, that the effective treatment of biofilms in the future will depend on tailoring treatment strategies to specific infection conditions rather than to any general phenomenon common to all biofilms.

Understanding biofilm resistance to antibacterial agents